UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Clinical infectious diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1304 - 1306
BRIEF REPORTS | Simeprevir | HBV/HCV coinfection | Acute hepatitis | HBV reactivation | Sofosbuvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Sofosbuvir - therapeutic use | Coinfection | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Hepatitis B - virology | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis B virus - physiology | Simeprevir - therapeutic use | Hepatitis B - complications | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Drug Therapy, Combination | Hepatitis | Care and treatment | Research | Hepatitis C virus | Disease prevention | Infectious diseases | Antibiotics | Drug therapy | Patients | Index Medicus
Journal Article
Liver international, ISSN 1478-3223, 06/2016, Volume 36, Issue 6, pp. 798 - 801
sofosbuvir | Cirrhosis | Chronic hepatitis C | end‐stage renal disease | simeprevir | severe renal impairment | kidney transplant | renal failure | liver transplantation | End-stage renal disease | Simeprevir | Kidney transplant | Severe renal impairment | Renal failure | Sofosbuvir | Liver transplantation | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Glomerular Filtration Rate | Liver Cirrhosis - complications | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Kidney Failure, Chronic - therapy | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Texas | Kidney Failure, Chronic - complications | Female | Aged | Sofosbuvir - adverse effects | Sustained Virologic Response | Drug Therapy, Combination | Renal Dialysis | Chronic kidney failure | Analysis | Liver | Transplantation of organs, tissues, etc | Genetic aspects | Hepatitis C | Liver cirrhosis | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2015, Volume 64, Issue 2, pp. 292 - 300
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Direct-acting antiviral | Genotype 1 | NS5A inhibitor | All-oral therapy | Hepatitis C virus | NS3 protease inhibitor | Hepatitis C virus; Genotype 1 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Drug Administration Schedule | Humans | Imidazoles - adverse effects | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | DNA, Viral - analysis | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Dose-Response Relationship, Drug | Simeprevir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Drug Monitoring | Health aspects | Genetic aspects | Index Medicus | Antiviral Agents | Hepatitis C, Chronic | Ribavirin | Life Sciences | Imidazoles | DNA, Viral | Hepacivirus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1497 - 1504
sofosbuvir | simeprevir | HIV | hepatitis C | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | HIV-1 | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Middle Aged | Male | Simeprevir - therapeutic use | Simeprevir - adverse effects | Viral Load | Simeprevir - administration & dosage | Hepatitis C - epidemiology | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Risk Factors | Treatment Outcome | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | New York City - epidemiology | Hepacivirus | Care and treatment | Research | Hepatitis C | HIV (Viruses) | Clinical trials | Hepatitis | Viruses | Human immunodeficiency virus--HIV | Pharmaceuticals | Virology | Index Medicus | and Commentaries
Journal Article
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 03/2016, Volume 121, pp. 197 - 203
Therapeutic drug monitoring | HCV protease inhibitor | Simeprevir | Solid-phase extraction | TMC435 | HPLC–UV | HPLC-UV | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Simeprevir - chemistry | Simeprevir - blood | Simeprevir - pharmacology | Reproducibility of Results | Chromatography, High Pressure Liquid - methods | Spectrophotometry, Ultraviolet - methods | Drug Stability | Humans | Plasma - chemistry | Hepatitis C virus | Methods | High performance liquid chromatography | Phosphates | Protease inhibitors | Proteases | Analysis | Nitriles | Health aspects | Index Medicus
Journal Article
Journal of viral hepatitis, ISSN 1352-0504, 04/2017, Volume 24, Issue 4, pp. 287 - 294
sofosbuvir | simeprevir | hepatitis C | daclatasvir | Gastroenterology & Hepatology | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral Agents - pharmacokinetics | United States | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Imidazoles - pharmacokinetics | Simeprevir - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Simeprevir - pharmacokinetics | Simeprevir - administration & dosage | Adult | Female | Sofosbuvir - pharmacokinetics | Sofosbuvir - adverse effects | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Aged | Hepatic Insufficiency - etiology | Hypertension | Antiviral agents | Medical research | Metabolites | Medicine, Experimental | Hepatitis C virus | Health aspects | Liver cirrhosis | Index Medicus
Journal Article
Journal of hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects | Index Medicus
Journal Article
Liver transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Gastroenterology & Hepatology | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Index Medicus | Medicin och hälsovetenskap
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | Index Medicus
Journal Article